FDA Clearance Tracker · P160030-S052
FreeStyle Libre 14-day Flash Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jan 17, 2023
Approved
Time to decision
29 days
Received Dec 19, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160030-S052
- Device name
- FreeStyle Libre 14-day Flash Glucose Monitoring System
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Dec 19, 2022
- Decided
- Jan 17, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P160030
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study.
Source documents
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.